B+
Bull case
15%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
YDES
Breeze AcquisitionFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-23
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+5.3
Score
AI commentary
Company-originated news is directionally constructive but thin, centered on the July 2 laboratory-footprint update and the older FY2025 release. The packet provides a $2.21 anchor price on 2026-07-22 but no controlled post-earnings event-window return. Social, options, short-interest, and employee-sentiment data are unavailable; the neutral values above indicate missing coverage, not positive evidence. No reliable analyst revision or target-change signal was found.
RankAlpha Sentiment Codex - 2026-07-23
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-23eventPost-earnings verification remains unresolvedMedium impact
The queue identifies 2026-07-20 as an earnings date, but the verified company materials available are the FY2025 results and a July 2 operating update. No confirmed July 20 release, consensus surprise, guidance change, analyst revision, or attributed post-print reaction was found. This is a monitoring item rather than a confirmed positive catalyst. [#PR-EARNINGS-2026-05-01]
2026-10-21eventEG BioMed transaction decisionHigh impact
The proposed EG BioMed merger remains a non-binding transaction expected by the company to close in 2026, subject to definitive agreements, approvals, and other conditions. Completion could broaden the diagnostics platform, while delay or failure would remove a key strategic narrative. [#PR-2026-07-02]
2026-10-21catalystDiagnostics footprint follow-throughHigh impact
YD Bio reported that affiliated laboratory licensing expanded its authorized U.S. footprint to 46 states plus Washington, D.C. and Guam, supporting early cancer-detection testing and real-world molecular-data generation. The announcement is already public; incremental value depends on demonstrated utilization and monetization. [#PR-2026-07-02]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology